Bristol Myers Squibb

FDA Approval

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb

Collaboration

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

Bristol Myers Squibb

Diversity

Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts

Bristol Myers Squibb

FDA

FDA Accepts for Priority Review Bristol Myers Squibb’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia

Bristol Myers Squibb

Healthcare

Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.

Bristol Myers Squibb

Digital Therapeutics

Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

Bristol Myers Squibb

Bristol-Myers Squibb Announces Update for Patients with Resected High-Risk Melanoma and PD-L1 <1%

Bristol Myers Squibb

M&A

Bristol-Myers Squibb Provides Update on Pending Merger with Celgene

Bristol Myers Squibb

M&A

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company

Bristol Myers Squibb

FDA Approval

U.S. Food and Drug Administration Approves Opdivo®(nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer

Bristol Myers Squibb

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab)

Bristol Myers Squibb

Collaboration

Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics

Bristol Myers Squibb

Oncology

Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy

Bristol Myers Squibb

Strategic Collaboration

Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214

Bristol Myers Squibb

Immuno-Oncology

European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Bristol Myers Squibb

Innovation

Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment

Bristol Myers Squibb